Supplementary Table 1. Mobility of mice infected and treated

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dpi | 10 | 12 | 14 | 16 | 18 | 20 | 22 | 24 |
| No infected | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
| *T. cruzi* | +++ | +++ | ++ | ++ | ++ | ++ | + | + |
| *T. cruzi* + A21 | +++ | +++ | +++ | ++ | ++ | ++ | ++ | + |
| *T. cruzi* + Bz | +++ | +++ | +++ | ++ | ++ | ++ | ++ | + |
| *T. cruzi* + A21 + Bz | +++ | +++ | +++ | +++ | +++ | ++ | ++ | ++ |

+++ Good exploratory activity, good mobility

++ Reduced exploratory activity, reduced mobility

+ Little exploratory activity, little mobility

Supplementary Table 2. Ergosterol content in *T. cruzi* epimastigotes

|  |  |
| --- | --- |
|  | Ergosterol content (%)  Mean ± SD |
| Medium | 100 |
| A21 0.5 M | 46.5 ± 6.9\* |
| A21 10.0 M | 24.6 ± 3.0\* |
| Bz 10.0 M | 93 ± 2.8 |

\*Significant difference vs. control (medium) p<0.05